Claude drug development partnerships
Anthropic's first results from six drug-developer partnerships, including 35,000 antibody designs and an 89% drop in document-review time.
Overview
On October 27, 2026 Anthropic published early results from research partnerships with six drug developers and its own programs; most work is preclinical. Divergence Labs generated about 35,000 antibody designs in roughly a month, of which three of 20 IgE-dislodging designs beat the standard medication. BigHat Biosciences tested about 1,010 variants in about 10 weeks, with the best binding more than 10x more tightly. Enveda's reviewers took under 3 hours instead of over 25 on 1,061 pages, a drop of 89%, and Claude caught all 11 human-found issues plus 7 more. Generate Biomedicines saw a design about 70% shorter than standard, and Bristol Myers Squibb uses Claude on clinical trial plans. Anthropic also acquired Mithril Medicine.
This is a sourced directory entry. Features and capabilities are reported in the linked sources; this entry does not document independent Aymorphic testing.
Key features
- Divergence Labs: about 35,000 antibody designs in a month, 3 of 20 IgE-dislodging designs beat the standard drug
- BigHat: 1,010 variants in about 10 weeks; best bound over 10x more tightly
- Enveda: 1,061 pages reviewed with an 89% cut in review time
- Generate Biomedicines: CAR T design about 70% shorter than standard
- Bristol Myers Squibb: clinical-trial plan analysis, expansion planned for 2027
Use cases
- Antibody and protein design workflows
- Regulatory and manufacturing documentation review
- Estimating clinical trial likelihood of success
Pricing
unknown; partnership program, no pricing published.
Pricing reflects the source record and may change. Confirm current terms with the provider.
Dates and sources
- Released
- 27 Oct 2026
- Record updated
- 29 Oct 2026
- Record last checked
- 29 Oct 2026